Latest News
Zymeworks Inc.
- Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
- Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- Roche bets up to $813M on Zymeworks lung cancer candidate
- Roche Licenses Zymeworks’ ZW209 Cancer Therapy
- Zymeworks licenses cancer therapy to Roche for up to $813m
- Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
- Form 8K Zymeworks Inc For: 23 October By Investing.com
- Zymeworks licenses cancer drug candidate ZW209 to Roche for $55m
- Zymeworks enters global license agreement with Roche for ZW209 after stock ends session up 1%
- Roche picks up trispecific engager from Zymeworks in deal worth $813M
- Zymeworks EVP Schayowitz sells $357,557 in shares By Investing.com
- Zymeworks closes out acquisition of Theravance for USD 929m
Headlines from the last 30 days, linking to the original publishers. See all market news →